Kazutoshi Isobe
Toho University
CancerInternal medicineRadiologySurgeryPathologyOncologyRetrospective cohort studyLung cancerChemotherapyLungT790MIdiopathic pulmonary fibrosisEpidermal growth factor receptorGefitinibAdenocarcinomaNon small cellIn patientCancer researchMedicineBiologyGastroenterology
122Publications
12H-index
1,129Citations
Publications 122
Newest
#1Yoshinori KikuchiH-Index: 12
#2Hideaki ShimadaH-Index: 56
Last. Yoshinori IgarashiH-Index: 25
view all 7 authors...
Source
#1Susumu SakamotoH-Index: 19
#2Hiroshige ShimizuH-Index: 6
Last. Kazutoshi IsobeH-Index: 12
view all 9 authors...
Source
#1Akira Iyoda (Toho University)H-Index: 31
#2Yoko Azuma (Toho University)H-Index: 3
Last. Atsushi Sano (Toho University)H-Index: 4
view all 8 authors...
Source
#1Yui Shimanuki (Toho University)
#2Kazutoshi Isobe (Toho University)H-Index: 12
Last. Kazuma Kishi (Toho University)H-Index: 22
view all 7 authors...
Source
#1Yoko Azuma (Toho University)H-Index: 3
#2Atsushi Sano (Toho University)H-Index: 4
Last. Akira Iyoda (Toho University)H-Index: 31
view all 10 authors...
BACKGROUND Chronic obstructive pulmonary disease (COPD) is an important risk factor for postoperative complications and mortality. To determine the effects of perioperative combination therapy, using a long-acting muscarinic antagonist (LAMA) and a long-acting β2 agonist (LABA), on preoperative lung function, postoperative morbidity and mortality, and long-term outcome in COPD patients. METHODS Between January 2005 and October 2019, 130 consecutive patients with newly diagnosed COPD underwent su...
Source
#1Kazutoshi Isobe (Toho University)H-Index: 12
#2Takahiro Yoshizawa (Toho University)H-Index: 2
Last. Kazuma Kishi (Toho University)H-Index: 22
view all 14 authors...
Background The response rate for osimertinib is high among patients with untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, there exist no biomarkers to predict the efficacy of the same. This study investigated whether BIM-γ mRNA expression in circulating tumor cells (CTCs) predicts poor outcomes for osimertinib treatment in patients with EGFR mutation-positive NSCLC. Methods Patients with advanced EGFR-tyrosine kinase inhibitor-untre...
1 CitationsSource
#1Akira Iyoda (Toho University)H-Index: 31
#2Yoko Azuma (Toho University)H-Index: 3
Last. Keigo TakagiH-Index: 11
view all 10 authors...
OBJECTIVES Silicone airway stents are used to manage central airway stenosis or obstruction, although their impact on long-term survival remains unknown in patients with central airway stenosis or obstruction due to thoracic malignancy. In this study, we retrospectively analyzed the impact of silicone stents on survival. METHODS We retrospectively analyzed clinical data of 106 patients with central airway stenosis or obstruction due to thoracic malignancy treated by stenting at Toho University O...
Source
#1Shugo UematsuH-Index: 5
#2Atsushi SanoH-Index: 4
Last. Akira IyodaH-Index: 31
view all 10 authors...
Background Although platinum-based chemotherapy is accepted as adjuvant chemotherapy for resectable advanced non-small cell lung cancer (NSCLC), its completion rate is low due to severe adverse events. S-1 plus cisplatin is associated with relatively low toxicity and an unimpaired quality of life, and has been used for unresectable advanced lung cancer. We investigated the acceptability and feasibility of combination therapy with S-1 plus cisplatin as postoperative adjuvant chemotherapy followin...
1 CitationsSource
#1Susumu Sakamoto (Toho University)H-Index: 19
#2Hiroshige Shimizu (Toho University)H-Index: 6
Last. Sakae Homma (Toho University)H-Index: 31
view all 7 authors...
BACKGROUND Pirfenidone treatment can slow decline in forced vital capacity (FVC) in idiopathic pulmonary fibrosis (IPF). However, its effects for usual interstitial pneumonia (UIP) with pleuroparenchymal fibroelastosis-like lesions (UIP+PPFELL) and UIP with nonspecific interstitial pneumonia (UIP+NSIP) are unclear. OBJECTIVES The aim of study is to assess pirfenidone effectiveness for UIP+PPFELL and UIP+NSIP. METHODS We retrospectively analysed data from 58 IPF patients treated with pirfenidone ...
1 CitationsSource
Background Although immune checkpoint inhibitors (ICIs) are promising in the treatment of advanced cancer, their use is associated with immune-related adverse events (irAEs) that affect endocrine organ systems. Although development of irAEs was associated with improved cancer-specific survival, the risk of irAEs is unclear. We investigated the association of pre-ICI comorbidities-including diabetes-with irAEs, overall survival (OS), and progression-free survival (PFS) in advanced lung cancer. Me...
Source